Drugs / PF-06439535 (CN)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04325698 | Jun 2020 → May 2021 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06439535 (CN) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04325698 ↗ |
| Route | Intravenous | “15 mg/kg, IV on day 1 of each 21 day cycle” NCT04325698 ↗ |